Toxic complications of high doses of treîsulfan in children: experience of the N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

Hematopoietic stem cell transplantation (HSCT) is a treatment method for a number of severe malignant and non-tumor diseases. Autologous (auto) and allogeneic (allo) HSCT improves outcomes in patients with solid and hematological malignancies. The toxicity of conditioning regimens before HSCT is often a limiting factor for successful transplant outcomes. The most common manifestations of visceral and tissue toxicity are epithelial (dermatological and mucosal) toxicity, hepatotoxicity, and neurotoxicity. Reducing the incidence of toxic complications of preparative regimens preceding HSCT is the optimization of accompanying therapy, and and individualized selection of doses of chemotherapy. In our study, among 119 HSCT cases performed in 2021–2022, treosulfan-containing preparative regimens were used. Dermatological toxicity was diagnosed in 80.0 %, mucositis – in 100 %, hepatotoxicity – in 18.5 % of observations, no neurological toxicity was recorded.

1. Aliev T.Z., Machneva E.B., Sidorova N.V., Belysheva T.S., Valiev T.T., Kirgizov K.I. Skin damage after the hematopoietic stem cell transplantation. Literature review. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2020;19(2):184–92. (In Russ.).

2. Belysheva T.S., Aliev T.Z., Valiev T.T., Machneva E.B., Sidorova N.V., Murashkin N.N., Kirgizov K.I., Varfolomeeva S.R. Clinical Features of Cutaneous Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cells Transplantation in Children with HematoOncological Diseases. Voprosy sovremennoj pediatrii = Current Pediatrics. 2020;19(6):500–8. (In Russ.).

3. Bolognia J.L., Cooper D.L., Glusac E.J. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9. doi: 10.1016/j.jaad.2008.05.018.

4. Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., Palmer J., Weisdorf D., Treister N.S., Cheng G.S., Kerr H., Stratton P., Duarte R.F., McDonald G.B., Inamoto Y., Vigorito A., Arai S., Datiles M.B., Jacobsohn D., Heller T., Kitko C.L., Mitchell S.A., Martin P.J., Shulman H., Wu R.S., Cutler C.S., Vogelsang G.B., Lee S.J., Pavletic S.Z., Flowers M.E.D. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi: 10.1016/j.bbmt.2014.12.001.

5. Epstein J.B., Schubert M.M. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park). 2003;17(12):1767–79; discussion 1779–82, 1791–2. PMID: 14723014.

6. Carreras E., Dufour C., Mohty M., Kröger N., eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer, 2019. PMID: 32091673.

7. Wachowiak J., Sykora K.W., Cornish J., Chybicka A., Kowalczyk J.R., Gorczyńska E., Choma M., Grund G., Peters C.; EBMT Pediatric Diseases Working Party. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 2011;46(12):1510–8. doi: 10.1038/bmt.2010.343.

8. Główka F.K., Romański M., Wachowiak J. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opin Investig Drugs. 2010;19(10):1275–95. doi: 10.1517/13543784.2010.517744. PMID: 20836619.

9. Wachowiak J., Sykora K.W., Cornish J., Chybicka A., Kowalczyk J.R., Gorczynska E., Choma M., Grund G., Peters C. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT Pediatric Diseases Working Party. Bone Marrow Transplant. 2011;46:1510–8. doi: 10.1038/bmt.2010.343.

10. Slatter M.A., Boztug H., Pötschger U., Sykora K.-W., Lankester A., Yaniv I., Sedlacek P., Glogova E., Veys P., Gennery A.R., Peters C., Inborn Errors EBMT, Parties PDW. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50:1536–41. doi: 10.1038/bmt.2015.171.

11. Morillo-Gutierrez B., Beier R., Rao K., Burroughs L., Schulz A., Ewins A.M., Gibson B., Sedlacek P., Krol L., Strahm B., Zaidman I., Kalwak K., Talano J.A., Woolfrey A., Fraser C., Meyts I., Müller I., Wachowiak J., Bernardo M.E., Veys P., Sykora K.W., Gennery A.R., Slatter M. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128(3):440–8. doi: 10.1182/ blood-2016-03-704015. Erratum in: Blood. 2016;128(21):2585. PMID: 27216217.

12. Ten Brink M.H., Zwaveling J., Swen J.J., Bredius R.G., Lankester A.C., Guchelaar H.J. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19(10):1572–86. doi: 10.1016/j.drudis.2014.04.005.

13. Van der Stoep M.Y.E.C., Bertaina A., Ten Brink M.H., Bredius R.G., Smiers F.J., Wanders D.C.M., Moes D.J.A.R., Locatelli F., Guchelaar H.J., Zwaveling J., Lankester A.C. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179(5):772–80. doi: 10.1111/bjh.14960.

14. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauff man R.E. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67. doi: 10.1056/NEJMra035092.

15. Scheulen M.E., Hilger R.A., Oberhoff C., Casper J., Freund M., Josten K.M., Bornhäuser M., Ehninger G., Berdel W.E., Baumgart J., Harstrick A., Bojko P., Wolf H.H., Schindler A.E., Seeber S. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000;6(11):4209–16. PMID: 11106234.

16. Rosman I.S., Lloyd B.M., Hayashi R.J, Bayliss S.J. Cutaneous eff ects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575–8. doi: 10.1016/j.jaad.2007.12.037.

17. Tkachenko P.E., Ivashkin V.T., Maevskaya M.V. Clinical guidelines for the correction of hepatotoxicity induced by anticancer therapy. Malignant tumors. 2020;10(3s2-2):52–65. doi: 10.18027/2224-5057-2020-10-3s2-40.

18. Ivanikov I.O., Vinogradova N.N., Krashenkov O.P., Kotselapova E.Yu., Grigorieva Yu.V., Myasnikova E.V., Pikunova I.N. Treatment of the chemotherapy induced hepatotoxicity. Dokazatel’naya gastroenterologiya = Russian Journal of EvidenceBased Gastroenterology. 2020;9(4):7–15. (In Russ.).

19. Levi M., Stemmer S.M., Stein J., Shalgi R., Ben-Aharon I. Treosulfan induces distinctive gonadal toxicity compared with busulfan. Oncotarget. 2018;9(27):19317–27. doi: 10.18632/oncotarget.25029.

20. Feit P.W., Rastrup-Andersen N., Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4- butanediol 4-methanesulfonate. J Med Chem. 1970;13(6):1173–5. doi: 10.1021/jm00300a034. PMID: 5479859.

21. Romański M., Ratajczak W., Główka F. Kinetic and mechanistic study of the pH-dependent activation (epoxidation) of prodrug treosulfan including the reaction inhibition in a borate buff er. J Pharm Sci. 2017;106:1917–22. doi: 10.1016/j.xphs.2017.03.018.